A CLINICAL RESEARCH LC-MS/MS METHOD FOR THE ANALYSIS OF ANTIDEPRESSANTS IN PLASMA

Significance of the Topic

Effective monitoring of antidepressants in plasma is critical for pharmacokinetic research, therapeutic drug monitoring, and understanding drug interactions. A robust method that supports multiple analytes with high sensitivity accelerates clinical studies and improves treatment optimization.

Objectives and Study Overview

This study describes the development and validation of a liquid chromatography–tandem mass spectrometry (LC-MS/MS) assay capable of quantifying ten commonly prescribed antidepressants in human plasma. The goal was to achieve rapid analysis, minimal sample volume, and reliable performance across a wide concentration range.

Methodology and Instrumentation

Sample preparation relies on protein precipitation:

• Fifty microliters of plasma mixed with 150 µL internal standard in acetonitrile.
• Vortex agitation followed by centrifugation and dilution of the supernatant.

Chromatographic separation and detection:

• UPLC system with an XSelect Premier HSS T3 column (2.1×100 mm, 2.5 µm).
• Gradient elution using water, acetonitrile, and ammonium acetate.
• Xevo TQD mass spectrometer in positive electrospray ionization with multiple reaction monitoring.
• Five-minute run time per injection.

Main Results and Discussion

Method validation demonstrated:

• Linearity or quadratic calibration over concentration ranges (e.g., 7.7–1300 ng/mL for several analytes).
• Low-level sensitivity with precision ≤20% CV and bias ≤15% at the lower limit, except minor deviation for fluvoxamine.
• Precision better than 10% CV across low, mid, and high pools.
• Negligible matrix effects (normalized matrix factors 0.90–1.07) with internal standard compensation.
• No carryover or significant interference from common endogenous substances.

Benefits and Practical Applications

The method’s advantages include:

• Minimal sample volume requirement (50 µL).
• Fast and simple sample preparation.
• Short analysis time suitable for high-throughput studies.
• Simultaneous quantification of a comprehensive panel of antidepressants.

Future Trends and Applications

Potential developments may include:

• Integration with automated workflows for greater throughput.
• Expansion to additional analytes or metabolites.
• Application to other biological matrices, such as cerebrospinal fluid or dried blood spots.
• Adoption of high-resolution mass spectrometry for broader screening.

Conclusion

This LC-MS/MS approach offers a reliable, efficient solution for simultaneous antidepressant quantification in plasma, supporting clinical research and therapeutic monitoring with high precision and throughput.